Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9545
Abstract: 9545Background: Combination ipi and nivolumab is approved for advanced melanoma and is in trials across oncology. Toxicity (tox) most often occurs 6-10 wks into treatment. Whether early tox is hard... read more here.
Keywords: combination; hyperacute toxicity; combination ipilimumab; toxicity combination ... See more keywords